Mary A. Cifaldi

Learn More
BACKGROUND AND OBJECTIVES Rheumatoid arthritis (RA) causes considerable disability and often results in loss of work capacity and productivity. This study evaluated the impact of adalimumab, a tumour necrosis factor antagonist with demonstrated efficacy in RA, on long-term employment. METHODS Data from an open-label extension study (DE033) of 486 RA(More)
OBJECTIVES This study evaluated the patients' perspective of burden of disease among 505 patients with severe, long-standing rheumatoid arthritis receiving adalimumab. METHODS Health-related quality-of-life and resource use data were collected during a 144-week open-label study. RESULTS Adalimumab maintained pain control and reduced the duration of(More)
OBJECTIVE To describe dosing patterns for tumor necrosis factor (TNF) antagonists in patients with rheumatoid arthritis from health care provider and payer point of interest. RESEARCH DESIGN AND METHODS Using privately insured US claims data from 31 large employers covering 31 companies across the US, rheumatoid arthritis (RA) patients were identified and(More)
OBJECTIVE To evaluate the effects of adalimumab on patient-reported outcomes of joint-related and skin-related functional impairment, health-related quality of life, fatigue and pain in patients with psoriatic arthritis (PsA). METHODS Patients with moderately- to severely- active PsA were treated with adalimumab, 40 mg, every other week, or placebo, in(More)
OBJECTIVE To estimate comprehensive cost of rheumatoid arthritis (RA) patients to society and individual stakeholders, including patients/employees, employers, family members/caregivers, and government. RESEARCH DESIGN AND METHODS Administrative claims databases covering privately insured and Medicare and Medicaid beneficiaries in the US were used to(More)
OBJECTIVE To evaluate household and work place outcomes for patients with rheumatoid arthritis (RA) who were homemakers or employed workers, respectively, and who were treated with adalimumab plus methotrexate versus methotrexate monotherapy. We also determined baseline predictors of household and work place outcomes. METHODS Data were from a health(More)
OBJECTIVE To estimate the excess risk of cardiovascular and cerebrovascular diseases among individuals with ankylosing spondylitis (AS) in Quebec compared with the general population of Quebec. METHODS A retrospective cohort study was conducted using population-based administrative data from Quebec. The cohort included all adult individuals with at least(More)
INTRODUCTION Biologic therapies have demonstrated efficacy and safety in several chronic systemic disorders. The authors indirectly compared response rates and costs per responder associated with biologic treatments for moderate-to-severe Crohn's disease (CD), psoriasis (Ps), and/or rheumatoid arthritis (RA). METHODS A systematic literature search was(More)
BACKGROUND Rheumatoid arthritis (RA) is a chronic autoimmune disease that often results in joint pain, inflammation and bone erosions. Perhaps the most notable change in RA treatment during the last decade is the advent of biologics, and, in particular, anti-tumour necrosis factor agents. Given these advances, it is useful to assess how healthcare and(More)
BACKGROUND Rheumatoid arthritis (RA) causes pain and serious functional impacts and substantially affects patients' daily lives, including their ability to work. OBJECTIVE This review examines recent studies of patients with RA treated with TNF antagonists and the impacts these therapies have on the workplace. METHODS A total of 133 articles and 14(More)